Oncology CROs in France

Mid-size global CRO under ALTEN Group formed by integrating Cmed and Larix, with deep oncology, rare disease, and cell/gene therapy clinical trial expertise across the US and Europe.

French CRO providing Phase I-III clinical trial management and monitoring services across France and Western Europe, with expertise in rare disease and orphan drug development.

Transatlantic Phase 1 CRO with clinical pharmacology units in Rennes (France) and Newark (NJ, USA). Specializes in first-in-human, CNS, cardiac safety, and abuse liability studies.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

Paris-based European CRO providing clinical operations, pharmacovigilance, and regulatory affairs services across 40+ countries with particular strength in oncology and rare disease.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

French mid-size CRO specialising in Phase I-III clinical trials, biostatistics, and regulatory affairs with offices in Paris and North Africa.